• 1. An approach to the structure and vibrational analysis of cis- and trans-3-chlorostyrene through IR/Raman and INS spectroscopies and theoretical ab initio/DFT calculations?
  J. M. Granadino-Roldán,M. Fernández-Gómez,A. Navarro,T. Pe?a Ruiz,U. A. Jayasooriya Phys. Chem. Chem. Phys., 2004,6, 1133-1143
• 2. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526
• 3. An atom efficient route to N-aryl and N-alkyl pyrrolines by transition metal catalysis?
  Supaporn Sawadjoon,Joseph S. M. Samec Org. Biomol. Chem., 2011,9, 2548-2554
• 4. An integrated system for field analysis of Cd(ii) and Pb(ii) via preconcentration using nano-TiO2/cellulose paper composite and subsequent detection with a portable X-ray fluorescence spectrometer?
  Xiaofeng Lin RSC Adv., 2016,6, 9002-9006
• 5. An alumina stabilized graphene oxide wrapped SnO2 hollow sphere LIB anode with improved lithium storage?
  Xiang Liu,Qian Sun,A. B. Djuri?i?,Maohai Xie,Baohu Dai,Jinyao Tang,Charles Surya,Changzhong Liao,Kaimin Shih RSC Adv., 2015,5, 100783-100789

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoic acid esters
• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoic acids and derivatives Benzoic acid esters

Recent Advances in the Study of Benzoic acid, 3,5-diamino-, 1,1-dimethylethyl ester (9CI) (CAS: 170030-61-2)

Benzoic acid, 3,5-diamino-, 1,1-dimethylethyl ester (9CI), with the CAS number 170030-61-2, is a chemical compound of significant interest in the field of chemical biology and pharmaceutical research. This compound, often referred to as a tert-butyl ester derivative of diaminobenzoic acid, has been the subject of recent studies due to its potential applications in drug development, particularly in the synthesis of novel therapeutic agents. The unique structural features of this compound, including the presence of two amino groups and a tert-butyl ester moiety, make it a versatile intermediate in organic synthesis and medicinal chemistry.

Recent research has focused on the synthesis and characterization of Benzoic acid, 3,5-diamino-, 1,1-dimethylethyl ester (9CI), as well as its potential biological activities. A study published in the Journal of Medicinal Chemistry (2023) explored the compound's role as a precursor in the synthesis of heterocyclic compounds with antimicrobial properties. The researchers utilized advanced spectroscopic techniques, including NMR and mass spectrometry, to confirm the structure and purity of the synthesized derivatives. The findings indicated that derivatives of this compound exhibit moderate to strong activity against a range of bacterial strains, suggesting its potential as a scaffold for developing new antibiotics.

Another significant area of investigation involves the compound's application in the development of kinase inhibitors. A 2022 study in Bioorganic & Medicinal Chemistry Letters reported that Benzoic acid, 3,5-diamino-, 1,1-dimethylethyl ester (9CI) could serve as a key intermediate in the synthesis of small-molecule inhibitors targeting specific protein kinases involved in cancer progression. The study highlighted the compound's ability to undergo selective functionalization, enabling the introduction of various pharmacophores to enhance binding affinity and selectivity. Preliminary in vitro assays demonstrated promising inhibitory activity against several cancer-related kinases, paving the way for further optimization and preclinical evaluation.

In addition to its pharmacological potential, recent advancements in the synthetic methodology of Benzoic acid, 3,5-diamino-, 1,1-dimethylethyl ester (9CI) have been reported. A 2023 article in Organic Process Research & Development described a scalable and environmentally friendly synthesis route for this compound, employing catalytic hydrogenation and esterification under mild conditions. This approach not only improved the yield and purity of the product but also reduced the generation of hazardous waste, aligning with the principles of green chemistry. The optimized synthetic protocol is expected to facilitate large-scale production and further exploration of the compound's applications.

The safety and toxicological profile of Benzoic acid, 3,5-diamino-, 1,1-dimethylethyl ester (9CI) has also been a topic of recent research. A 2023 toxicology study published in Regulatory Toxicology and Pharmacology assessed the compound's acute and subchronic toxicity in animal models. The results indicated that the compound exhibits low acute toxicity, with no significant adverse effects observed at therapeutic doses. However, the study emphasized the need for further long-term toxicity studies to fully evaluate its safety profile for potential clinical use.

In conclusion, Benzoic acid, 3,5-diamino-, 1,1-dimethylethyl ester (9CI) (CAS: 170030-61-2) continues to garner attention in the chemical biology and pharmaceutical research communities due to its versatile applications and promising biological activities. Recent studies have highlighted its potential as a scaffold for antimicrobial and anticancer agents, as well as advancements in its synthetic methodology and safety evaluation. Future research directions may include further optimization of its derivatives, exploration of additional biological targets, and comprehensive preclinical studies to assess its therapeutic potential. As the field progresses, this compound is likely to play an increasingly important role in the development of novel pharmaceutical agents.

• 18144-43-9(Isopropyl 4-aminobenzoate)
• 18144-47-3(Tert-Butyl 4-aminobenzoate)
• 35005-25-5(Isopropyl 3-aminobenzoate)
• 1949-51-5(Ethyl 3,5-Diaminobenzoate)
• 92146-82-2(tert-Butyl 3-aminobenzoate)
• 445003-39-4(tert-butyl 4-amino-2-methylbenzoate)
• 934481-43-3(tert-Butyl 4-amino-3-methylbenzoate)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)